Citigroup says Endo still a buy

Endo Pharmaceuticals Holdings, Inc. was reiterated by Citigroup Investment Research analyst Andrew Swanson a buy rating after third-quarter results showed earnings of $0.58, exceeding Citigroup's forecast and consensus by $0.03. Citigroup said Endo shares fell victim to inflated expectations as investors hoping for an Oxycontin blowout were let down. The company's improving fundamentals and strong growth prospects make it Citigroup's top pick in the group. Shares of the Chadds Ford, Pa., specialty pharmaceutical company were up $0.75, or 3.03%, at $25.50 on volume of 1,984,655 shares versus the three-month running average of 1,079,480 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.